Edited by Melvin D. Yahr. Price, $15.95. Pp 303. Raven Press, 15 West 84th St, New York, NY 10024, 1973.
This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
This second volume contains 16 reports that were the major presentations of a conference on Parkinson disease held on Nov 28,1972. This conference was jointly sponsored by the Parkinson's Disease Foundation and Merck Sharp and Dohme Research Laboratories. The editor and publisher have done an extraordinary job of getting the book on the market while the information is still new.
The contributors constitute a virtual "Who's Who of basic and clinical research" related to the biochemistry and pharmacology of parkinsonism and can be accepted as highly authoritative sources in their respective areas. The 277 pages of text are quite varied with respect to the degree of sophistication required of the reader but, in general, those reports with prospective clinical application are easily comprehended. The general conclusion is that dopa decarboxylase inhibitors offer a worthwhile addition to the clinician's armamentarium and provide the researcher with a tool for further disecting
Buchanan DS. Advances in Neurology: Treatment of Parkinsonism—The Role of Dopa Decarboxylase Inhibitors.. Arch Intern Med. 1974;134(1):191. doi:10.1001/archinte.1974.00320190193065